A detailed history of Mc Lean Asset Management Corp transactions in Amgen Inc stock. As of the latest transaction made, Mc Lean Asset Management Corp holds 923 shares of AMGN stock, worth $271,851. This represents 0.09% of its overall portfolio holdings.

Number of Shares
923
Previous 908 1.65%
Holding current value
$271,851
Previous $292 Million 1.04%
% of portfolio
0.09%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$309.38 - $337.38 $4,640 - $5,060
15 Added 1.65%
923 $295 Million
Q2 2024

Jul 11, 2024

BUY
$262.75 - $319.31 $6,043 - $7,344
23 Added 2.6%
908 $292 Million
Q1 2024

Apr 10, 2024

BUY
$268.87 - $324.56 $1,882 - $2,271
7 Added 0.8%
885 $239 Million
Q3 2023

Oct 11, 2023

BUY
$218.65 - $271.46 $191,974 - $238,341
878 New
878 $238 Million
Q1 2023

Apr 11, 2023

SELL
$225.79 - $275.2 $35,674 - $43,481
-158 Reduced 15.74%
846 $205 Million
Q4 2022

Jan 19, 2023

BUY
$229.03 - $291.01 $13,512 - $17,169
59 Added 6.24%
1,004 $264 Million
Q3 2022

Oct 12, 2022

SELL
$224.46 - $253.15 $673 - $759
-3 Reduced 0.32%
945 $216,000
Q2 2022

Jul 07, 2022

BUY
$230.71 - $256.74 $11,304 - $12,580
49 Added 5.45%
948 $232,000
Q1 2022

Apr 08, 2022

BUY
$219.27 - $242.57 $3,069 - $3,395
14 Added 1.58%
899 $217,000
Q4 2021

Jan 14, 2022

SELL
$198.88 - $227.6 $47,731 - $54,624
-240 Reduced 21.33%
885 $205,000
Q3 2021

Oct 27, 2021

BUY
$212.27 - $248.7 $4,033 - $4,725
19 Added 1.72%
1,125 $235,000
Q2 2021

Jul 19, 2021

SELL
$233.58 - $259.14 $8,175 - $9,069
-35 Reduced 3.07%
1,106 $274,000
Q1 2021

Apr 28, 2021

SELL
$221.91 - $258.6 $2,219 - $2,586
-10 Reduced 0.87%
1,141 $291,000
Q4 2020

Jan 27, 2021

BUY
$216.38 - $257.67 $249,053 - $296,578
1,151 New
1,151 $265,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Mc Lean Asset Management Corp Portfolio

Follow Mc Lean Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Lean Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mc Lean Asset Management Corp with notifications on news.